Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending

Adial Pharmaceuticals

11/05/2026 13:38

Overview

U.S. addiction therapies developer's Q1 net loss narrowed from prior year on lower R&D spending

Company highlighted regulatory changes that may speed AD04 approval and reduce development costs

Adial set collaboration framework with Molteni for potential AD04 commercialization in Europe

Outlook

Company expects existing cash to fund operations into the second half of 2026

Result Drivers

LOWER R&D SPENDING - Co said Q1 research and development expenses fell due to decreased CMC activity and no new data analytics projects

HIGHER BUSINESS DEVELOPMENT COSTS - Co said Q1 general and administrative expenses rose due to increased business development costs

Company press release: ID:nGNX9d27W1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is $25.00, about 1,648.3% above its May 8 closing price of $1.43

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)